Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer
NCT02289144 · University of Texas Southwestern Medical Center · PHASE2 · withdrawn · last registry update 2019-07-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “study was on hold for protocol redesign; decided to not move forward with study.” | – | Registry record, University of Texas Southwestern Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ALK within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-06-09Results posted on the registry: Novartis Pharmaceuticals, Ceritinib (NCT01742286)
- 2020-05-05Results posted on the registry: Children's Oncology Group, Crizotinib (NCT00939770)
- 2020-03-09Results posted on the registry: Genentech, Inc., Entrectinib Form A + Entrectinib Form C (NCT03796013)
- 2020-03-05Also stopped (withdrawn): Takeda, Brigatinib + Brigatinib AAF (NCT04260009)
- 2020-02-26Results posted on the registry: Genentech, Inc., Entrectinib Test Formulation (F1) + Entrectinib Reference Formulation (F06) (NCT03796260)
- 2020-02-21Results posted on the registry: Novartis Pharmaceuticals, Ceritinib (NCT02336451)
- 2020-02-20Also stopped (terminated): SWOG Cancer Research Network, crizotinib + pemetrexed disodium (NCT02134912)
- 2020-01-27Results posted on the registry: University of California, San Francisco, Capmatinib + Ceritinib (NCT02587650)
- 2020-01-27Also stopped (terminated): University of California, San Francisco, Capmatinib + Ceritinib (NCT02587650)
- 2019-12-27Also stopped (terminated): Novartis Pharmaceuticals, Ceritinib (LDK378) (NCT02465528)
- 2019-12-17Also stopped (terminated): National Cancer Institute (NCI), PF-02341066/PF-00299804 + PF-02341066/PF-00299804 (NCT01441128)
- 2019-11-25Results posted on the registry: Dana-Farber Cancer Institute, Alectinib (NCT03131206)
- 2019-10-21Results posted on the registry: Novartis Pharmaceuticals, Ceritinib (LDK378) (NCT02465528)
- 2019-10-10Also stopped (withdrawn): University of Washington, Brentuximab Vedotin + Ceritinib (NCT02729961)
- 2019-08-05Results posted on the registry: National Cancer Institute (NCI), Carboplatin + Cisplatin (NCT01822496)
- 2019-08-05Also stopped (terminated): National Cancer Institute (NCI), Carboplatin + Cisplatin (NCT01822496)
- 2019-07-11Results posted on the registry: Hoffmann-La Roche, Alectinib + Crizotinib (NCT02838420)
- 2019-07-05Phase 3 first posted: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., TQ-B3139 + Crizotinib (NCT04009317)
- 2019-07-01Results posted on the registry: Pfizer, Crizotinib + Pembrolizumab (NCT02511184)
- 2019-07-01Also stopped (terminated): Pfizer, Crizotinib + Pembrolizumab (NCT02511184)
- 2019-06-21Results posted on the registry: Pfizer, axitinib + crizotinib (NCT01999972)
- 2019-05-01Results posted on the registry: SWOG Cancer Research Network, crizotinib + pemetrexed disodium (NCT02134912)
- 2019-03-14Phase 3 first posted: Federal Research Institute of Pediatric Hematology, Oncology and Immunology, Crizotinib (NCT03874273)
- 2019-02-12Results posted on the registry: Novartis Pharmaceuticals, LDK378 (NCT01685138)
- 2019-01-25Results posted on the registry: Pfizer, PF-06463922 + rifampin (NCT02804399)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision